Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.

BACKGROUND: Infectious complications and associated mortality are a major concern in acute pancreatitis. Enteral administration of probiotics could prevent infectious complications, but convincing evidence is scarce. Our aim was to assess the effects of probiotic prophylaxis in patients with predic...

Повний опис

Бібліографічні деталі
Автори: Besselink, MG, van Santvoort, H, Buskens, E, Boermeester, M, van Goor, H, Timmerman, H, Nieuwenhuijs, V, Bollen, T, van Ramshorst, B, Witteman, B, Rosman, C, Ploeg, R, Brink, M, Schaapherder, A, Dejong, C, Wahab, P, van Laarhoven, C, van der Harst, E, Eijck, v, Cuesta, M, Akkermans, L, Gooszen, H
Формат: Journal article
Мова:English
Опубліковано: 2008
_version_ 1826265830338330624
author Besselink, MG
van Santvoort, H
Buskens, E
Boermeester, M
van Goor, H
Timmerman, H
Nieuwenhuijs, V
Bollen, T
van Ramshorst, B
Witteman, B
Rosman, C
Ploeg, R
Brink, M
Schaapherder, A
Dejong, C
Wahab, P
van Laarhoven, C
van der Harst, E
Eijck, v
Cuesta, M
Akkermans, L
Gooszen, H
author_facet Besselink, MG
van Santvoort, H
Buskens, E
Boermeester, M
van Goor, H
Timmerman, H
Nieuwenhuijs, V
Bollen, T
van Ramshorst, B
Witteman, B
Rosman, C
Ploeg, R
Brink, M
Schaapherder, A
Dejong, C
Wahab, P
van Laarhoven, C
van der Harst, E
Eijck, v
Cuesta, M
Akkermans, L
Gooszen, H
author_sort Besselink, MG
collection OXFORD
description BACKGROUND: Infectious complications and associated mortality are a major concern in acute pancreatitis. Enteral administration of probiotics could prevent infectious complications, but convincing evidence is scarce. Our aim was to assess the effects of probiotic prophylaxis in patients with predicted severe acute pancreatitis. METHODS: In this multicentre randomised, double-blind, placebo-controlled trial, 298 patients with predicted severe acute pancreatitis (Acute Physiology and Chronic Health Evaluation [APACHE II] score > or =8, Imrie score > or =3, or C-reactive protein >150 mg/L) were randomly assigned within 72 h of onset of symptoms to receive a multispecies probiotic preparation (n=153) or placebo (n=145), administered enterally twice daily for 28 days. The primary endpoint was the composite of infectious complications--ie, infected pancreatic necrosis, bacteraemia, pneumonia, urosepsis, or infected ascites--during admission and 90-day follow-up. Analyses were by intention to treat. This study is registered, number ISRCTN38327949. FINDINGS: One person in each group was excluded from analyses because of incorrect diagnoses of pancreatitis; thus, 152 individuals in the probiotics group and 144 in the placebo group were analysed. Groups were much the same at baseline in terms of patients' characteristics and disease severity. Infectious complications occurred in 46 (30%) patients in the probiotics group and 41 (28%) of those in the placebo group (relative risk 1.06, 95% CI 0.75-1.51). 24 (16%) patients in the probiotics group died, compared with nine (6%) in the placebo group (relative risk 2.53, 95% CI 1.22-5.25). Nine patients in the probiotics group developed bowel ischaemia (eight with fatal outcome), compared with none in the placebo group (p=0.004). INTERPRETATION: In patients with predicted severe acute pancreatitis, probiotic prophylaxis with this combination of probiotic strains did not reduce the risk of infectious complications and was associated with an increased risk of mortality. Probiotic prophylaxis should therefore not be administered in this category of patients.
first_indexed 2024-03-06T20:29:46Z
format Journal article
id oxford-uuid:30a80d7e-c78f-4fb0-ac1f-773e82621425
institution University of Oxford
language English
last_indexed 2024-03-06T20:29:46Z
publishDate 2008
record_format dspace
spelling oxford-uuid:30a80d7e-c78f-4fb0-ac1f-773e826214252022-03-26T13:02:51ZProbiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:30a80d7e-c78f-4fb0-ac1f-773e82621425EnglishSymplectic Elements at Oxford2008Besselink, MGvan Santvoort, HBuskens, EBoermeester, Mvan Goor, HTimmerman, HNieuwenhuijs, VBollen, Tvan Ramshorst, BWitteman, BRosman, CPloeg, RBrink, MSchaapherder, ADejong, CWahab, Pvan Laarhoven, Cvan der Harst, EEijck, vCuesta, MAkkermans, LGooszen, H BACKGROUND: Infectious complications and associated mortality are a major concern in acute pancreatitis. Enteral administration of probiotics could prevent infectious complications, but convincing evidence is scarce. Our aim was to assess the effects of probiotic prophylaxis in patients with predicted severe acute pancreatitis. METHODS: In this multicentre randomised, double-blind, placebo-controlled trial, 298 patients with predicted severe acute pancreatitis (Acute Physiology and Chronic Health Evaluation [APACHE II] score > or =8, Imrie score > or =3, or C-reactive protein >150 mg/L) were randomly assigned within 72 h of onset of symptoms to receive a multispecies probiotic preparation (n=153) or placebo (n=145), administered enterally twice daily for 28 days. The primary endpoint was the composite of infectious complications--ie, infected pancreatic necrosis, bacteraemia, pneumonia, urosepsis, or infected ascites--during admission and 90-day follow-up. Analyses were by intention to treat. This study is registered, number ISRCTN38327949. FINDINGS: One person in each group was excluded from analyses because of incorrect diagnoses of pancreatitis; thus, 152 individuals in the probiotics group and 144 in the placebo group were analysed. Groups were much the same at baseline in terms of patients' characteristics and disease severity. Infectious complications occurred in 46 (30%) patients in the probiotics group and 41 (28%) of those in the placebo group (relative risk 1.06, 95% CI 0.75-1.51). 24 (16%) patients in the probiotics group died, compared with nine (6%) in the placebo group (relative risk 2.53, 95% CI 1.22-5.25). Nine patients in the probiotics group developed bowel ischaemia (eight with fatal outcome), compared with none in the placebo group (p=0.004). INTERPRETATION: In patients with predicted severe acute pancreatitis, probiotic prophylaxis with this combination of probiotic strains did not reduce the risk of infectious complications and was associated with an increased risk of mortality. Probiotic prophylaxis should therefore not be administered in this category of patients.
spellingShingle Besselink, MG
van Santvoort, H
Buskens, E
Boermeester, M
van Goor, H
Timmerman, H
Nieuwenhuijs, V
Bollen, T
van Ramshorst, B
Witteman, B
Rosman, C
Ploeg, R
Brink, M
Schaapherder, A
Dejong, C
Wahab, P
van Laarhoven, C
van der Harst, E
Eijck, v
Cuesta, M
Akkermans, L
Gooszen, H
Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.
title Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.
title_full Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.
title_fullStr Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.
title_full_unstemmed Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.
title_short Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.
title_sort probiotic prophylaxis in predicted severe acute pancreatitis a randomised double blind placebo controlled trial
work_keys_str_mv AT besselinkmg probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT vansantvoorth probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT buskense probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT boermeesterm probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT vangoorh probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT timmermanh probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT nieuwenhuijsv probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT bollent probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT vanramshorstb probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT wittemanb probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT rosmanc probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT ploegr probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT brinkm probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT schaapherdera probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT dejongc probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT wahabp probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT vanlaarhovenc probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT vanderharste probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT eijckv probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT cuestam probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT akkermansl probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial
AT gooszenh probioticprophylaxisinpredictedsevereacutepancreatitisarandomiseddoubleblindplacebocontrolledtrial